| 1. |
Antoncelli L, Bucca C, Neri M, et al.Asthma severity and medical resource utilzation.Eur Respir J, 2004, 23:723-729.
|
| 2. |
Hanania NA, Alpan O, Hamilos DL, et al.Omalizumab in severe allegic asthma inadequately controlled with standard therapy:a randomized tria1.Ann Intern Med, 2011, 154:573-582.
|
| 3. |
Bousquet J, Cabrera P, Berkman N, et al.The effect of treatment with omalizumab, an anti-IgE antibody, on asthma exacerbations and emergency medical visits in patients with severe persistent asthma.Allergy, 2005, 60:302-308.
|
| 4. |
Solar M, Matz J, Townley R, et al.The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics.Eur Respir J, 2001, 18:254-261.
|
| 5. |
Buhl R, Matz J, Townleyz R, et al.Omalizumab provides longterm control in patient with moderate-to-severe allergic asthma.Eur Respir J, 2002, 20:73-78.
|
| 6. |
Brusselle G, Michils A, Louis R, et al."Real-life"effectiveness of omalizumab in patients with severe persistent allersle asthma:The PERSIST study.Respir Med, 2009, 103:1633-1642.
|
| 7. |
Hitt E.Omalizumab improves asthma control in inner-city children.N Engl J Med, 2011, 364:1005-1015.
|
| 8. |
Berger W, Gupta N, McAlary M, et al.Evaluation of long-term safety of anti-IgE antibody, omalizumab, in children with allergic asthma.Allergy Asthma Immunol, 2003, 91:182-188.
|
| 9. |
Global Strategy for asthma management and prevention.Global initiative for asthma.2010, 66-105.www.ginasthma.org/pdf/GINARepo~2010.
|
| 10. |
Corren J, Lemanske RF, Hanania NA, et al.Lebrikizumab treatment in adults with asthma.N Engl J Med, 2011, 365:1088-1098.
|
| 11. |
Piper E, Brightling C, Niven R, et al.A phaseⅡplacebo-controlled study of tralokinumab in moderate-to-severe asthma.Eur Respir J, 2013, 41:330-338.
|
| 12. |
Wenzel S, Ford L, Pearlman D, et al.Dupilumab in persistent asthma with elevated eosinophil levels.N Engl J Med, 2013, 368:2455-2466.
|
| 13. |
Nair P, Pizzichini MM, Kjarsgaard M, et al.Mepolizumab for prednisone-dependent asthma with sputum eosinophilia.N Engl J Med, 2009, 360:985-993.
|
| 14. |
Haldar P, Brightling CE, Hargadon B, et al.Mepolizumab and exacerbations of refractory eosinophilic asthma.N Engl J Med, 2009, 360:973-984.
|
| 15. |
Pavord ID, Korn S, Howarth P, et al.Mepolizumab for severe eosinophilic asthma (DREAM):a multicentre, double-blind, placebo-controlled trial.Lancet, 2012, 380:651-659.
|
| 16. |
Castro M, Mathur S, Hargreave F, et al.Reslizumab for poorly controlled, eosinophilic asthma:a randomized, placebo-controlled study.Am J Respir Crit Care Med, 2011, 184:1125-1132.
|
| 17. |
Russo C, Polosa R.TNF-alpha as a promising therapeutic target in chronic asthma:a lesson from rheumatoid arthritis.Clin Sci (Lond), 2005, 109:135-142.
|
| 18. |
Cazzola M, Polosa R.Anti-TNF-alpha and Th1 cytokine-directed therapies for the treatment of asthma.Curr Opin Allergy Clin Immunol, 2006, 6:43-50.
|
| 19. |
Berry MA, Hargadon B, Shelley M, et al.Evidence of a role of tumor necrosis factor alpha in refractory asthma.N Engl J Med, 2006, 354:697-708.
|
| 20. |
Morjaria JB, Chauhan AJ, Babu KS, et al.The role of a soluble TNFalpha receptor fusion protein (etanercept) in corticosteroid refractory asthma:a double blind, randomised placebo-controlled trial.Thorax, 2008, 63:584-591.
|
| 21. |
Holgate ST, Noonan M, Chanez P, et al.Efficacy and safety of etanercept in moderate-to-severe asthma:a randomised, controlled trial.Eur Respir J, 2011, 37:1352-1359.
|
| 22. |
Erin EM, Leaker BR, Nicholson GC, et al.The effects of a monoclonal antibody directed against tumor necrosis factor-[alpha]in asthma.Am J Respirv Crit Care Med, 2006, 174:753-762.
|
| 23. |
TailléC, Poulet C, Marchand-Adam S, et al.Monoclonal anti-TNF-αantibodies for severe steroid-dependent asthma:a case series.Open Respir Med J, 2013, 7:21-25.
|
| 24. |
Wenzel SE, Barnes PJ, Bleecker ER, et al.A randomized, double-blind, placebo-controlled study of tumor necrosis factor-alpha blockade in severe persistent asthma.Am J Respir Crit Care Med, 2009, 179:549-558.
|
| 25. |
Busse WW, Israel E, Nelson HS, et al.Daclizumab improves asthma control in patients with moderate to severe persistent asthma:a randomized, controlled trial.Am J Respir Crit Care Med, 2008, 178:1002-1008.
|
| 26. |
Parker JM, Oh CK, LaForce C, et al.Safety profile and clinical activity of multiple subcutaneous doses of MEDI-528, a humanized anti-interleukin-9 monoclonal antibody, in two randomized phase 2a studies in subjects with asthma.BMC Pulm Med, 2011, 28:11-14.
|
| 27. |
Hacha J, Tomlinson K, Maertens L, et al.Nebulized anti-IL-13 monoclonal antibody Fab'fragment reduces allergen-induced asthma.Am J Respir Cell Mol Biol, 2012, 47:709-717.
|
1/5
WeChat